Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Heart Failure, Congestive

In brief

Different doses of relaxin will be compared to placebo to determine efficacy and safety for the treatment of patients hospitalized with acute heart failure

Key facts

Study ID

NCT00520806

Run by

Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies

People needed

1161

Starts

2007-10-01

Expected to finish

2012-09-01

Last updated by the study team

2012-10-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Hospitalized for acute heart failure
• Dyspnea at rest or with minimal exertion
• Pulmonary congestion
• Able to provide informed consent
• Systolic blood pressure > 125 mmHg
• Impaired renal function defined as an eGFR of 30-75 mL/min/1.73m2

You may not qualify if…

• Use of other IV therapies for acute heart failure
• Fever or sepsis
• Recent major neurologic event
• Recent major surgery
• Recent acute coronary syndrome
• Other recent investigational drug use

Where it is running

• Northwestern University — Chicago, Illinois, United States
• Wayne State University/Detroit Receiving Hospital — Detroit, Michigan, United States
• Heart Institute — Safed, Israel

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.